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ONCE pain, homorrhage, and infection were brought under reasonable control,
and as our knowledge of normal and abnormal function became more secure,
the magnitude of an operation could be extended nearly indefinitely. Many
operations came to be looked upon as subtotal eviscerations. Surgeons often
believed that the end results of the surgery for many malignant tumours would
be greatly improved merely by extending the limits of resection. Unfortunately,
we have come to know that once malignant disease has spread beyond the organ
of its origin, it is all too often extraordinarily difficult to eradicate. While the
end results of surgery for cancer of the major viscera have without doubt
improved during the last twenty-five years, they have not improved sufficiently
to still the search for better methods of therapy.
We must admit that the time to cure cancer, except in occasional instance, is
when it is strictly a local disease. Early diagnosis and early adequate operation,
or adequate radiation for a limited group of the malignancies, are the only means
at our disposal for significantly inlcreasing the number of five- and ten-vear
survivals free from the disease. Even then we cannot be sure of cure.
Unfortunatelv, surgeons must now admit that further extension of surgical or
radiation therapy gives little hope of greatlv improving the presently accepted
end results.
Dr. Michael Shimkin, in his paper before the Fourth National Cancer
Conference, said, "Our opponent is tough and elusive. Our victories are un-
comfortably small and our progress is painfully slow. But there have been
indubitable victories, and there is continued progress. Our steps forward
empower us to maintain our optimism.
"One manifestation of our progress is that our concepts regarding cancer
have not remained static. A whole series of changed and changing ideas and
approaches has occurred during the past few vears, many since the last National
Cancer Conference in Detroit in 1956.
"This, of course, is not surprising. All of medicine shares in the technological
revolution of our times. Discoveries and opportunities are upon us at a rate
that exceeds available resources of men, space, and time to exploit them. Cancer
research certainly is not an exception."
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cThere are too many generalizations concerning cancer. All too frequently
it is spoken of as if it were a single disease. The intimation is that the life history
of cancer in a major viscus is always the same. Actually we know that it is often
not the same disease even in the same organ. In some instances the lesion spreads
so slowly that one wonders whether it is truly a malignant lesion, and in other
instances a cancer which histologically looks quite similar spreads as rapidly as
a prairie fire.
Thoughtful interniists, surgeons, and radiologists realize more than ever before
the present inadequacies of therapy. The majority of these individuals admit
freely that once malignant disease has spread beyond the organ of its origin it
is nearly impossible to eradicate. It must be freely admitted that cancer confronts
the surgeon with many of his most difficult and exasperating problems. Three
and five years survivals for such common carcinomas as those of the stomach and
the breast taken as a whole do not exceed 10 and 30 per cent. respectivelv, where
there has been no selection of cases.
An obvious way to improve these data is to establish the diagnosis earlier in
an attempt to forestall the spread of the disease beyond the range of the scalpel.
Extensive education of physicians and laity has been undertaken. Diagnostic
methods are being improved. Pathologic examinations of cells exfoliated from
the surfaces of the lung and uterus offer promise for the diagnosis of early not
easily accessible cancers, and may be widely applicable to cancers of hollow
organs, although as yet they have not been proven to be as useful as we had
initially hoped they would be. Cancer cells can be found in the blood stream
of patients with cancer of certain of the major viscera, and this finding is so
frequent that one woniders why any patient can ever survive once the disease
has been initiated.
Due to the insidious nature of the disease, its failure to produce svmptoms
in its incipienlt stages, and its often extremelv rapid spread to distant locationls,
it is evident that under the best practical conditions of diagniosis and technical
liberty, surgerv, as we know it now, can anticipate a level of efficiency w%ell
below a desirable standard. We shall have to find more potent adjuncts of therapy
before cancer is better controlled. We must have a keener insight into the
character of cancerous tissues, their failure to conform wvith normal cellular
organization, and their energetic metabolic needs.
Extirpation of tissue alone, or in conjunction with radiotherapy is perhaps, at
present, the best available regimen. Their possibilities are perhaps not yet ex-
hausted, but we must begin to look for other means of therapy as the limitations
of these older methods have been reached. The surgeoni rightly in my own
country has been aligning himself with other investigators into the nature of
neoplastic tissue. There can be no phase of this subject for which the surgeon
does not have a pertinent concern. Surgeons must know what is being done in
research in malignant disease and must vigorously assist in the clinical application
of the research findings.
Antibiotic and chenmotherapeutic agents have assisted greatly in the surgical
care of suppurative infectionls. The surgical treatnment of certain patients wvith
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unsurmountably perilous, has been revised, not because of streptomycin, but
because of the w ider knowledge of the physiologic basis of thoracic surgery
and the increased knowledge of the disease itself. Due to the poorly understood,
but unequivocal inhibitory influence of the spleen on the cellular elements of
the blood, splenectomv is a dramatic therapy for certain anrmias, leukopenias,
and thrombocytopenias, and the syndromne of depression of all three elements,
hypersplenism, or primary splenic panhematocvtopenia.
In ni-anv of our university institutionis and in certain of our distinguished
cancer institutes, and no doubt in similar institutions in your own country,
individuals are concernied with basic research in order that new knowledge may
assist in unravelling the problems associated with the causes and nature of
malignant disease. In many of these institutions, and especially in many of our
great hospitals, other individuals, primarily clinicianis who have had varying
amlounits of traininig in good clinical research, are playing significant roles in the
chemotherapy of late malignant disease with the hope that through the use of
a variety of chemotherapeutic agents which are being made available, we may
find better methods for the complete therapy of malignant tumours.
I am suire that there exists areas in which our concepts of cancer are not
changing as rapidlv as the facts warrant. There are many areas where the
application of research findings has lagged. The clinician must play his full part
in this work. Who else knows the life history of clinical cancer so well?
A number of young surgeons are participating actively in the use of
chemotherapeutic agents which are being administered to patients at the time of
operation for cancer of- the lung, cancer of the stomach, cancer of the colon,
cancer of the prostate, and cancer of the ovarv. This is being done with the
hope that certaini of these agents will improve the end results which are now
being obtained by surgery, or by surgery anid X-ray alone. Already data are
available to show that in tlle case of mammary cancer this can be done.
I have had it said to me that the adjuvant chenmotherapy programme, as well
as certain aspects of the chemotherapy programmne in general, is an irrational
approach to the major problems of malignant disease. Individuals who support
this point of view believe that we must first have a fuller understanding of the
precise basic nature of cancer. The historv of medical progress does not support
their point of view. I am afraid that these individuals may not be fully conversant
with previous contributions to medicine wvhich over many, many years have
come to significantly effect a variety of disorders which have plagued mankind.
Lister knew verv little about bacteriology when he developed the aseptic
theory for the control of infection at operation. While Banting and Best made
insulin available in 1921, scientists have been working in the intervening years
in order that we might have a clearer concept of the manner in which insulin
acts. The sulphonamides became available in the mid-thirties, and ten years later
we were not sure of the biological processes by which these agents acted.
Penicillin became available in 1943, and within the next ten years an increasing
number of antibiotics became available for clinical therapy, at a time when it
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organisms causinig infection.
I milust agree with Paul Weiss when he said, "Real science is earthy; just onle
of nmany branches of the human enterprise; one to be cultivated, but nlot a cult.
Science mulst miiake more men its devotees, 1)ut nonie its priests."
Finialiv it is said bv manll internists in mV countrv that surgeons ought not
to be playin(yg a. significalnt role in the chemotherapy of nmalignant ttnl)ours.
I have on mlore than one occasion counselled mlly mnedical colleagues to read
Harvey Cushing's address on "Realignnments of the Greater Medicinie ancd
Surgerv," which address was given at the Third Interniational Congress On
Medicine and Surgerv in London in June, 1913. It was then that he said, "The
voung surgeonl of the future will be an interniist first and a surgeon later."
The surgeonis of this coUlltrv and of mine really control at one time or another
the mnajority of patients wvith solid maligniant tumours. Many of these individuals
are experieniced investigators and a worthwhile nuimiber of them have made
significant contributions to our basic knowledge of a variety of disordered states.
This is a field in which basic scientists, internists, and surgeons must work
together, each functionling in that particular area in wrhich he has a major interest.
Are we doing evervthing possible to advance research findings from the basic
science laboratory to the clinic? Unless we all rcalize our responsibilities, we
mav well be in the position of retarding progress. We must be awake to the
miianv exciting findings being uncovered in votur coutntrv and mine which have
a close relationship to the canicer probleml.
In an article on the "Chenmotherapy of Solid Tumours," bv Dr. Robert Glenn
Ravdin and XVillianm L. Elkinis the following statement is found, "The situation
at present in the chemnotherapy of solid tumours is perhaps comparable to that
in suirgery at the turn of the century or in radiotherapy some three decades ago:
ainumber of different techniques compete for attention, nost of which are
uinstalndardized, inadequately evaluated, heavilyv influenced by vogue and attend(le(d
by considerable morbidity, not to say hazard. At the same time, a fesv outstanid-
inglv brilliant accomplishments indicate that labours along these lines are not
fruitless. In order to lay a groundwork for a more specific discussionl, some
generalities can be first dealt with."
It cannot be denied that the chemotherapy of malignant tumours is a specialized
cndeavouir. Many of the agents are toxic and require considerable experience
in their administration. They do not act uniformly even on similar tumours.
There are available, however, a group of agents of varying chemical design
which do affect a variety of malignant tumours. These and related agents deserve
careful scrutinv through clinical trial. Such studies must be carried out in fairly
large-scaled programmes. We are even at this time not yet completely sure as
to the optimal dosage of certain of these agents, the rate of their administrationi,
and the method of their administration.
Some of these drugs are not toxic when given in minimal dosage, but it is
equially true that they are not cancerocidal unless they are administered to the
poinlt of toxicity. As Ravdin anld Elkins have pointed out, "The differential
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smiiall (for the agentts \e now lhave); a tumi)our will prol)ably not be affected
by a dose of drug which is not injurious to the miiore senlsitivC of the normiial
tissues: Tumlour cells share the common biochemical mechanisnms of normal
cells; extensive investigation at the biochemical level has turnied up only quanti-
tative differences, and manyv of these are not pronounced. Exploitation of these
differences has not reached a stage that may in any sense be described as refined.
Indeed, the mlost effective drugs seemi in cssence to affect cells in rough proportioin
to their growth rate, anid thereforc, in sonmewhat varying degree, to be particuilarly
nloxious to hematopoietic tissue and the gastrointestinal mucosa. However, the
concept of reaching a desired goal by subjecting a patient to an injurious
procedure is not foreign to the surgeoni. It should be noted parenthetically that
although chemlotherapeutic agenits mayn inlterfere with host resistance in certain
experimental situationis in animllals b)earlng tranisplanted ttumilours, there is no
convincing evi'dence that these findinigs miiay be extrapolated to spontaneous
tumours in the humaii. This is by nio mleans a closed question."
The idea that the progress of malignant diseases might be controlled in part
or in whole bv chenmotherapy is surely not a new one. Anidrogenls and estrogenis
have been demonstrated to retard the spread of certain malignant tumours of
the breast and to cause regression in areas of metastasis once this has taken place.
Other agents have l)een fotund to be useful in certain of the leukemias. It is an
unfortunate circumlstacLaie that while mlany of these agents have been found to be
extraordinarill useful in certain tumours of a mlalignanit nature found in ex-
perimenital aninmals that they have not been found to be useful when used in
similar tumours in nman. The agents that we are using are classified as alkylating
agents, antimetabolites, antibiotics, and a miscellaneous group of agents such as
the hormones.
The alkvlating agents, which are frequenitly called the mlustards, have been
used in a wide variety of malignant tumours. The exact mechanism by which
thev function is not as yet definitelv determined. These nitrogen mlustards, as
they are very comnmonly called, act by mlaking the nucleic acids as their targets.
Thio-TEPA, TEM, Myleran, anid Cytoxani or Endoxani belong to this general
group. Some of these can be given orally which is at tinmes a decided advantage.
Cytoxan rarely produces thrombocytopenia even in dosage levels which cause
serious reduction in the lymphocytes. This provides a safety feature which we
believe permits greater dosage than can be obtained with other alkylating agents.
In our hands they have been most effective against the lymphomals, reticuluml
cell sarcoma, ovarian anid nmanimarv carcinoma. While we have had some dramatic
results with the use of certain of these agents, the dramatic improvement shown
following therapy has been all too short. Perhaps readjustnments of the methods
of dosage of administration of the drug nlight chanige this, but wve mlust look
for more potent agents in this series.
The anitimetabolites constitute a group of diverse character which have the
common characteristic "of accurately counterfeiting somiie normiial cellular
conistituent."
11In the area of antibiotic therapy for tumours the miost wivdely used agent has
been actinomvcin D. It is a very effective agent for the cmbryonal carcinomas
of the kidniey, the Wilms' tumour. It is also effective in certain tumours of the
testis and in rhabdomyosarcomas and certain other undifferentiated sarconlas,
especially those in children.
We must attempt by every conceivable method to improve the activity of
these agents againist the malignant tumours, and at the same time to reduce
the toxicity, a task that nlow seemiis nearly hopeless. A large group of chemists
in and out of goveriinlenit, and in and out of our chemical inidustries and our
universities, are attempting to develop such additional agents for clinical trial
following careful pharmacological study and screening of the agents in experi-
mental systems. Certain individuals are suggesting combined therapy, and in
the choriocarcinomas of the testis, methotrexate, chlorambucil, and actinomycin
D used together have certainly proved to be superior to either one of these
agents used alone. Sonme investigators are rigorously attempting to find less toxic
agents which will potentiate the more effective toxic agents.
There is increasing evidence that radiation and chemotherapy will provide
end resuits which are better than those when either therapy is used alone. I'his
area is now being very carefully investigated.
Warren Cole suggested that greater salvage might be achieved by the concurrent
adminiistration of effective chemotherapeutic agents at the time of and immediately
subsequent to major surgical procedures. There is now evidence available to
show that in carcinoma of the breast this is true, and it is highly probable
that as more effective agents become available for other tumours, this attack
nmav be broadened.
I am sure that this audience is familiar with the method developed in
Dr. Creech's department at Tulane University in New Orleans and by other
surgical groups in which high concentrations of an effective agent are introduced
into an isolated circulation of a limited area. Thus, high concentrations of drugs
can be obtained without producing general toxicity. Whether this method will
prove of permanent usefulness remains vet to be determined but certain areas
of the body can be perfused in what is essenitially a closed vascular system.
I would hope that certain of the younger rnembers of this audience will become
sufficiently interested in this important area of effort to spend a portion of their
timne carefully studying the effect of a variety of agents now available and those
which will soon be available in careful clinical investigation. Beware of pitfalls
in this field! Subjective improvement is not a very reliable criterion. There are
manv pitfalls in this area which the cliical investigator must come to know.
Decrease in the volume of a measurable tumour mass is the most important
criterion of effect. It is anl unfortunate circumstance that so often one cannot
get bona fide measurenments. In some instances biochenmical properties of the
tumour prove to provide valuable criteria of effectiveness, but the most important
criterion is the extension of a useful life.
The organized Co-operative Clinical Studies now being carried on in my
country have yielded solid quanititative data in a nmuch shorter time thacn any
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co-operation of manv internists and surgeons in the care and chemotherapy of
advanced malignant disease. It has gained the confidence and active collaboration
of the pharmaceutical industry. The programme has assisted in the training of
hundreds of scientists and clinicians, not only in cancer research but in closely
related fields. It has organized a national standard reporting system of end results
in malignant disease, and such reports are now being made on more than 50,000
new cancer cases a year. It has developed biometric units in a number of our
nmedical schools and other research institutions to provide statistical consultation
not only for cancer chemotherapy, but for other research. It has made available
the first truly unselected, complete data on a national basis of operative compli-
cations and mortality fronm gastric, pulmonary, and colorectal resections, and it
has set the pattern for other research areas where extensive interinstitutional
efforts are needed.
The builk of the chemicals examined during the past two years have come
from the antibiotics programmes of industry and consist of crude beers. No
rational approach is possible in the selection of anti-cancer antibiotics. Great
skill anid experience, however, will account for the greater success of some
laboratories. This programme of necessity must be largely empirical.
The rapid progress in the study of hormone analogues could not have been
achieved by individual or unco-ordinated effort.
A similar study of the vast number of plant natural products is being
undertaken.
The three tumour mouse screen is being subjected to careful analysis. This
method, as well as all other screening methods, can be evaluated only when a
sufficient number of candidate compounds show true effectiveness against tumours
in man.
The vast majority of scientists interested in cancer chemotherapy are prepared
to drop any method of screening presently employed when a more specific
method is discovered. Until then it is essential to continue along the lines
presently followed.
Preclinical pharmacology must be expanded to meet the needs of the clinician.
It is understandable that pharmacologists are not anxious to undertake huge
programmes of preclinical pharmacology without assurance that the compound
is of real interest to clinicians. It is also clear that the clinician can evaluate the
anti-cancer properties of a compound more quickly and accurately if he has
precise information concerning time-dose relationships, excretion, metabolism,
and distribution in the tumour and in the body.
The co-operative clinical studies carried out with the aid of the Center through
its clinical panel have been responsible for achievements which could not have
been brought about by any other organizational pattern or sponsorship to my
knowledge. The large number of institutions and doctors who have voluntarily
agreed to study the response to anti-cancer agents are organised to work together
in small groups on the basis of protocols representative of specific experimental
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chemotherapeutic agents.
Extensive modifications may arise from the critical evaluations presently under
way. The greatest importance of the clinical co-operative trials lies in the fact
that a large-scale attempt has been effectively carried out for actual clinical
investigation based upon predetermined criteria. Data emanating from such
studies permit analysis which otherwise could not be possible. The goals of
individual studies in this co-operative plan were selected as much to achieve
familiarity with this kind of clinical investigation as for the purpose of clinical
investigation itself. It must be remembered that this kind of work is not as
exciting as research of an individual scientist. It calls for obedience to rules,
democratically achieved and agreed to. A by-product of such clinical interest
is the great improvement in the care of patients with advanced cancer, and the
conveyance of hope to the patient with such a serious problem because of the
increased tempo of research activity concerning his or her problem. An important
by-product, too, is the collection of information concerning the life history and
biologic behaviour of the various forms of cancer. These by-products alone are
worth the effort of the entire clinical programme so far.
Time does not permit me to describe the many exciting areas of research
that are being prosecuted. In 1956, at the Third National Cancer Conference,
Wendell Stanley suggested that for research purposes at least we might assume
that all human cancer was viral in origin. The evidence is becoming stronger
that Wendell Stanley may well be correct, and if he is, the justification of
chemotherapy will indeed be on a firmer basis.
While the gains have been substantial, we have not yet achieved the goal
wvhich we have set before us to achieve. I need not tell this audience that this
large field, which takes such a heavy toll each year in your country, and in
mine, and in many other countries in the world, will be solved. When it is we
will understand that understanding science is a way of thinking and that science's
task is to serve man.
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